AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30663869
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg baricitinib
Trial: 30663869
Drug: All-bari-RA (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All-bari-RA (all doses)
Trial: 27846612
Drug: High-dose plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose plerixafor (480 μg/kg)
Trial: 27846612
Drug: Conventional-dose plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional-dose plerixafor (240 μg/kg)
Trial: 25272318
Drug: PRP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP plus 2 ranibizumab injections
Trial: 21446219
Drug: Oral anti-oxidant
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anti-oxidant treatment (vitamin C-100 mg BD and vitamin E-400 IU BD) for 45 days
Trial: 15373936
Drug: Fumarate tablet
RxNorm normalized name: Ferrous Fumarate Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fumarate tablet (120 mg dimethylfumarate and 95 mg calcium‐monoethylfumarate) taken in the fasted state
Trial: 15373936
Drug: Fumarate tablet
RxNorm normalized name: Ferrous Fumarate Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fumarate tablet taken after a standardized breakfast
Trial: 11419825
Drug: Aspirin (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (81 mg every day or 325 mg every 3 days)
Trial: 9173339
Drug: Oral estrogen-progestin
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estrogen-progestin contraception
Trial: 8282457
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives for > 10 years
Trial: 26545392
Drug: Gait training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gait training combined with compelled weight-shift therapy (experimental group, n=14)
Trial: 20456839
Drug: Herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal medicine treatment plus Western medicine (group A)
Trial: 20456839
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine plus placebo (group B)
Trial: 11846968
Drug: Caffeine ingestion
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine ingestion (5 mg (kg body mass)(‐1))
Trial: 9569951
Drug: HDF 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDF 100 ml/min
Trial: 3289929
Drug: Iopamidol 150
RxNorm normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iopamidol 150 mg I/ml
Trial: 3289929
Drug: Iopamidol 200
RxNorm normalized name: iopamidol 200 mg iodine/mL (41 %) INJECTION VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopamidol 200 mg I/ml
Trial: 29580594
Drug: 10‐mL ice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐mL ice popsicle
Trial: 29580594
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of water at room temperature
Trial: 25130571
Drug: HM-derived cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HM-derived cream supplement
Trial: 15015273
Drug: Tianzhi Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianzhi Granule (TZK) 0.5 g/bag, taken one bag three times a day for two courses of one month each
Trial: 8739664
Drug: Mirtazapine, 15‐45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine, 15‐45 mg/day
Trial: 8739664
Drug: Amitriptyline, 30‐90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline, 30‐90 mg/day
Trial: 1884876
Drug: Bromhexine 72
RxNorm normalized name: bromhexine
DrugBank: Bromhexine (DB09019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromhexine 72 mg daily for one month
Trial: 22540851
Drug: Pulse radiofrequency
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse radiofrequency treatment at 42°C for 120 seconds to the dorsal root ganglion
Trial: 14970281
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with autologous tumor cells genetically modified with an adenoviral vector (Ad‐GM) to secrete GM‐CSF; Intradermal injections every 2 weeks for a total of three to six vaccinations
Trial: 8836336
Drug: Mizolastine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizolastine (10 mg once daily)
Trial: 7930305
Drug: Cetirizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (10 mg once daily)
Trial: 7410896
Drug: A/New Jersey
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A/New Jersey subvirion vaccine
Trial: 335000
Drug: Whole-virus vaccine
RxNorm normalized name: Rubella virus vaccine
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-virus vaccine
Trial: 7410896
Drug: Bivalent subvirion
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent subvirion vaccine
Trial: 23208460
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol (400 mg)
Trial: 23208460
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol (400 mg)
Trial: 20609098
Drug: Intramuscular lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular lipid
Trial: 18206407
Drug: Platelet-rich gel
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich gel (PRG) treatment
Trial: 18206407
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no PRG treatment)
Trial: 16339924
Drug: GnRH-receptor antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH-receptor antagonist (graded doses)
Trial: 8614377
Drug: Study solution
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study solution (25 microgram/ml of both amikacin and vancomycin added to the standard solution)
Trial: 8614377
Drug: Standard solution
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard solution (normal saline + 100 U/ml of heparin)
Trial: 1475987
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg oral dose of famotidine administered at 10:00 p.m.
Trial: 1475987
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg oral dose of famotidine administered at 6 p.m.
Trial: 3900079
Drug: Ioxaglate 320
RxNorm normalized name: ioxaglate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ioxaglate 320 mg/ml
Trial: 3900079
Drug: Ioxaglate 200
RxNorm normalized name: ioxaglate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ioxaglate 200 mg/ml
Trial: 24428754
Drug: Prasugrel 10
RxNorm normalized name: prasugrel 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 10 mg daily for 7 days
Trial: 24428754
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg daily for 7 days
Trial: 19887304
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (PLD) 40 mg/m² on day 1, continuous infusion ifosfamide (IFO) 1700 mg/m² on days 1-3, mesna, every 28 days for 6-9 cycles
Trial: 17823365
Drug: Statin/ACEI combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin/ACEI combination treatment at standard doses (STD, ramipril 2.5/simvastatin 20 mg, or atorvastatin 10 mg)
Trial: 17823365
Drug: Statin/ACEI combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin/ACEI combination treatment at high doses (HiDo, ramipril 10 mg, or enalapril 20 mg/simvastatin 80 mg, or atorvastatin 40 mg)
Trial: 17823365
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses (HiDo) treatment
Trial: 17823365
Drug: Standard doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doses (STD) treatment
Trial: 11057354
Drug: Patanol (olopatadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patanol (olopatadine hydrochloride ophthalmic solution 0.1%) with placebo tablet
Trial: 11057354
Drug: Claritin (loratadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Claritin (loratadine 10 mg) with placebo
Trial: 8363164
Drug: Psyllium, 5.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium, 5.1 g twice a day
Trial: 29993221
Drug: Bio-modulator patch
RxNorm normalized name: Bio-Kool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio-modulator patch
Trial: 26822397
Drug: Gastrectomy followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gastrectomy followed by chemotherapy
Trial: 23875987
Drug: WTQ-G advertisements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WTQ-G advertisements (graphic images)
Trial: 23875987
Drug: WTQ-T +
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WTQ-T + HTQ advertisements (combination)
Trial: 15108107
Drug: Submucosal epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Submucosal epinephrine injection (1/10,000)
Trial: 11666122
Drug: Oral TTFCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral TTFCA (60 mg tablets twice daily) for 4 weeks
Trial: 8013765
Drug: Propafenone (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (900 mg/daily)
Trial: 8013765
Drug: Flecainide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide (300 mg/daily)
Trial: 3057851
Drug: Diltiazem (260
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (260 mg/day)
Trial: 3057851
Drug: Hydrochlorothiazide (52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (52 mg/day)
Trial: 23370314
Drug: Paclitaxel and
RxNorm normalized name: paclitaxel and encequidar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel and carboplatin with conatumumab (3 mg/kg)
Trial: 23370314
Drug: Paclitaxel and
RxNorm normalized name: paclitaxel and encequidar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel and carboplatin with conatumumab (15 mg/kg)
Trial: 23370314
Drug: Conatumumab treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conatumumab treatment among V-allele carriers
Trial: 23370314
Drug: Conatumumab treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conatumumab treatment among F-allele homozygotes
Trial: 17601495
Drug: Paliperidone ER
RxNorm normalized name: Paliperidone ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone ER 6 mg
Trial: 17466492
Drug: Paliperidone ER
RxNorm normalized name: Paliperidone ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone ER 9 mg
Trial: 17601495
Drug: Paliperidone ER
RxNorm normalized name: Paliperidone ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone ER 12 mg
Trial: 17092691
Drug: Paliperidone ER
RxNorm normalized name: Paliperidone ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone ER (all doses)
Trial: 11152164
Drug: Complementary/alternative medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary/alternative medicine (CAM) therapies
Trial: 9186298
Drug: Oral ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ingestion of 100 g glucose (OGTT)
Trial: 9186298
Drug: 100-g protein
RxNorm normalized name: soy protein isolate 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-g protein meal
Trial: 8247951
Drug: Ketanserin 60
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 60 mg daily for 3 weeks
Trial: 8247951
Drug: Ketanserin 120
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 120 mg daily for 3 weeks
Trial: 3530444
Drug: Doxorubicin (ADR)
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (ADR) 75 mg/m2 by iv bolus every 3 weeks
Trial: 3530444
Drug: Doxorubicin (ADR)
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (ADR) 45 mg/m2 by iv bolus every 3 weeks and Mitomycin (MMC) 10 mg/m2 by iv bolus every 6 weeks
Trial: 24612915
Drug: 2 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml/kg 30% lipid emulsions
Trial: 20697169
Drug: Subcutaneous terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous terbutaline (250 μg) followed by oral terbutaline (20 mg/d) as maintenance
Trial: 20697169
Drug: Intravenous salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous salbutamol (0.1 mg) followed by oral salbutamol (24 mg/d) as maintenance
Trial: 1810356
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release metoclopramide 15 mg (Gastrobid Continus tablets) given twice daily
Trial: 1810356
Drug: Domperidone 10
RxNorm normalized name: domperidone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 10 mg given three times daily
Trial: 1810356
Drug: Domperidone 20
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 20 mg given three times daily
Trial: 1810356
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release metoclopramide and domperidone (both doses)
Trial: 6636262
Drug: Heparinized plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparinized plasma at 4.0 ng/ml
Trial: 6636262
Drug: Serum at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum at 4.0 ng/ml
Trial: 6636262
Drug: Standard preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preparation procedures
Trial: 28510741
Drug: Early FFP
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early FFP administration (FFP in the CPB priming solution)
Trial: 28510741
Drug: Late FFP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late FFP administration (FFP given immediately after CPB)
Trial: 20337077
Drug: One-visit endodontic
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-visit endodontic treatment
Trial: 21185738
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of mixed tocopherols 666 IU/day and alpha lipoic acid (ALA) 600 mg/day for 8 weeks
Trial: 18803070
Drug: Ziprasidone 80‐160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 80‐160 mg/day (n=147)
Trial: 18803070
Drug: Olanzapine 10‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 10‐20 mg/day (n=24)
Trial: 18803070
Drug: Risperidone 4‐8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 4‐8 mg/day (n=22)
Trial: 18803070
Drug: Quetiapine 300‐750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine 300‐750 mg/day (n=97)
Trial: 9825977
Drug: Erythromycin 40
RxNorm normalized name: erythromycin 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 40 mg/kg/d, intravenously or orally
Trial: 2668325
Drug: sc injections
RxNorm normalized name: SC 41930
DrugBank: SC 41930 (DB17101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sc injections of SMS 201‐995 every 2 hours (q2h)
Trial: 2668325
Drug: sc injections
RxNorm normalized name: SC 41930
DrugBank: SC 41930 (DB17101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sc injections of SMS 201‐995 every 8 hours (q8h)
Trial: 1245160
Drug: Clofibate preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofibate preparation 1
Trial: 1245160
Drug: Clofibate preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofibate preparation 2
Trial: 31525257
Drug: Xylocaine spray
RxNorm normalized name: Xylocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xylocaine spray (8 puffs of 10% Lidocaine, 80 mg)
Trial: 31525257
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no spray)
Trial: 26799692
Drug: Simeprevir 150
RxNorm normalized name: simeprevir 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simeprevir 150 mg once daily + Sofosbuvir 400 mg once daily for 12 weeks
Trial: 26799692
Drug: Simeprevir 150
RxNorm normalized name: simeprevir 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simeprevir 150 mg once daily + Sofosbuvir 400 mg once daily for 8 weeks
Trial: 24117232
Drug: Adjunctive moderate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive moderate dose lithium therapy
Trial: 24117232
Drug: Optimized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized treatment
Trial: 22530944
Drug: eGFR 30.0-59.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR 30.0-59.9 mL/min/1.73 m²
Trial: 22530944
Drug: eGFR ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR ≥ 90.0 mL/min/1.73 m²
Trial: 16926184
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with sulfasalazine and methotrexate (MTX)
Trial: 12760727
Drug: Intrasphincteric injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrasphincteric injections of botulinum toxin (group 1: 10 patients)
Trial: 12760727
Drug: Injections of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections of 1% polidocanol (group 2: 6 patients)
Trial: 12760727
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with botulinum toxin and polidocanol (group 3: 6 patients)
Trial: 9357940
Drug: HIV-infected patients
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-infected patients responding to antiretroviral therapy
Trial: 8453557
Drug: Regional RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional RT plus six cycles of CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Trial: 8453557
Drug: Regional RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional RT plus six cycles of CHOP chemotherapy
Trial: 3769386
Drug: Sotalol 160
RxNorm normalized name: sotalol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol 160 mg/day
Trial: 3769386
Drug: Sotalol 240
RxNorm normalized name: sotalol 240 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol 240 mg/day
Trial: 3769386
Drug: Sotalol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol (all doses)
Trial: 26543645
Drug: Dexmedetomidine, 1 µg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine, 1 µg/kg (group D)
Trial: 26543645
Drug: Midazolam, 0.02 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam, 0.02 mg/kg (group M)
Trial: 22080997
Drug: Real rTMS
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real rTMS (20 Hz, 10 second trains, intensity 80% of motor threshold) for 10 minutes daily for five consecutive days
Trial: 11456360
Drug: Valaciclovir 1000
RxNorm normalized name: valacyclovir 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valaciclovir 1000 mg three times daily for 7 days
Trial: 9623637
Drug: L-T4 replacement
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-T4 replacement treatment in hypothyroid patients
Trial: 25264024
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (4 mg/kg median)
Trial: 23553259
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of 4% lidocaine (anesthetized condition)
Trial: 19755925
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m2 (P500)
Trial: 19755925
Drug: Pemetrexed 1000
RxNorm normalized name: pemetrexed 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 1000 mg/m2 (P1000)
Trial: 17092968
Drug: TPA023 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPA023 0.5 mg
Trial: 17092968
Drug: TPA023 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPA023 1.5 mg
Trial: 11261347
Drug: Soft hydrogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft hydrogel contact lenses worn daily for 12 months